Virbac

Virbac (NYSE: VIRP) is a global veterinary pharmaceutical company dedicated exclusively to animal health. Founded in 1968 by French veterinarian Pierre-Richard Dick, Virbac develops, manufactures and distributes a wide range of products and services designed to prevent and treat health conditions in companion animals, livestock and aquaculture. The company reported annual revenue of EUR 1.22 billion in 2022.

Virbac's product portfolio includes:

• Vaccines

• Parasiticides

• Antibiotics

• Dermatology products

• Dental products

• Nutritional supplements

• Diagnostic tools

The company focuses on both companion animals (dogs, cats, horses) and production animals (cattle, pigs, poultry, sheep). Virbac has a strong emphasis on research and development, investing around 7-8% of its annual revenue into R&D activities. The company operates manufacturing facilities in 10 countries including France, US, Mexico, Brazil, and Vietnam.

Virbac has expanded its global presence through organic growth and acquisitions since the 1980s. The company now has operations in over 100 countries, with 33 subsidiaries and over 5,100 employees worldwide. Virbac is the 6th largest veterinary pharmaceutical company globally. The founding family of Pierre-Richard Dick retains majority voting rights in the publicly-traded company, which has been listed on the Paris Stock Exchange since 1985. Virbac's corporate headquarters are located in Carros, France.